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view of the current status of the knowledge on metabolo-
mics biomarkers for obesity, but further research is needed 
because the methods used in the studies to date are very 
homogenous, e.g. most used a targeted approach and there-
fore analyzed almost the same group of metabolites. More-
over, prospective studies are lacking since all of the studies 
are either case-control or cross-sectional studies. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 In the last decades, obesity has become a global public 
health burden in developed as well as in developing coun-
tries  [1, 2] . Obesity, as a worldwide growing epidemic, 
raises the need for better tools to monitor the disease ad-
equately and to enable better strategies for early preven-
tion and diagnosis.
 The increasing number of obese people in industrial-
ized countries is mainly related to modern lifestyle fac-
tors, including nutrition and leisure time activities. The 
strong association of obesity with type 2 diabetes (T2DM) 
 [3] , hypertension  [4] , and metabolic syndrome  [5] high-
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 Abstract 
 Background: The prevalence and incidence of obesity have 
become a major public health problem during the last de-
cades, but the underlying biochemical and metabolic pro-
cesses are not fully understood. Metabolomics, the science 
of small molecules of the metabolism, is helping to unravel 
these mechanisms via the identification of markers related 
to obesity. These biomarkers are used to prevent diseases in 
later life or for the early diagnosis of diseases. This review 
focuses on articles dealing with biomarkers for obesity.  Key 
Messages: Branched-chain amino acids (BCAA), nonesteri-
fied fatty acids, organic acids, acylcarnitines, and phospho-
lipids were identified as potential biomarkers for obesity. 
This indicates a relation between elevated BCAA, and other 
amino acids, and the obese state. Furthermore, deregulation 
of β-oxidation is associated with the development of obesi-
ty. The results have several limitations, including the differ-
ing ages of the subjects in the studies, the fact that all of the 
studies had a case-control design and therefore no causal 
explanatory power, and that most looked for similar metab-
olites and reported almost equal results.  Conclusion: The 
strength of this review is that it gives a comprehensive over-
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lights the need to investigate the development and persis-
tence of obesity. To handle obesity and its consequences, 
it is necessary to understand the underlying mechanisms 
of its pathology and its relation to nutrition.
 Unraveling the underlying mechanisms is also of spe-
cial interest in relation to the hypothesis of early pro-
gramming, which suggests that a high dietary protein 
content in early life leads to a greater weight gain and 
rapid growth in the first 2 years of life, which is further 
related to later obesity  [6] . To prevent adverse effects of 
early-life nutrition, one can search for biomarkers that 
represent the risk for the development of later diseases 
including obesity, T2DM, and metabolic syndrome. 
These biomarkers can be used for routine measurement 
of therapeutic or preventive responses. They can be found 
in body fluids such as blood or urine and can be small 
biological molecules, also called metabolites. The existing 
literature on metabolic precursors in obesity mainly com-
prises comparisons between lean and obese subjects and 
only a few focus on the metabolic precursors and altera-
tions underlying the obese phenotype, but this is of major 
interest. Predicting future health outcomes by investigat-
ing the metabolic phenotype, as is routinely performed in 
newborn screening  [7] , would be a major benefit for the 
prevention of obesity and insulin resistance in later life.
 One tool to search for biomarkers is targeted metabo-
lomics. Metabolomics examines the human metabolome 
to detect metabolites (small molecules with a molecular 
weight of less than 1,500 Da)  [8] , metabolic pathways, and 
their impairments. Therefore, biofluids, tissues, or ex-
tracts from cells are analyzed. The aim of many metabo-
lomics studies is to find highly predictive markers for 
pathophysiological processes or specific metabolic states. 
 The objective of this review is to present a comprehen-
sive overview of the current state of metabolomics chang-
es due to obesity in humans to provide insight into the 
process of obesity development and the influence of obe-
sity on insulin signaling on a molecular level. The aim was 
to identify specific articles dealing with the topic of anal-
ysis of the human metabolome using a metabolomics ap-
proach involving biomarkers for obesity or pre-obesity. 
 Methods 
 Literature Search Strategy 
 The literature search was conducted in the PubMed database 
(National Center for Biotechnology Information, US National Li-
brary of Medicine), due to its medical, biochemical, biological, and 
statistical content, from database inception to February 2014. The 
search was limited to papers with the full text available, written in 
English, and reporting on human beings in the setting of PubMed. 
There were no limitations for study design or population age. 
 ‘Obesity’ and its synonym ‘adiposity’ were the central search 
terms, together with ‘metabolome’ and its variants. The following 
5 steps were performed during the search on PubMed, using dif-
ferent combinations of search terms.
 The terms for the first step (1) were ‘Obesity or Adiposity and 
Metabolomic$’ and resulted in 97 hits. The second step (2) con-
sisted of the combination of ‘Obesity or Adiposity and Metabol * 
and Biomarker and Metabolomics’, resulting in 30 hits. The next 
step (3) was ‘Obesity or Adiposity and Metabol * and Biomarker 
not Metabolic Syndrome not Diabetes not Cancer not Gene * not 
Cardiovascular Disease not Insulin Resistance’, with 572 resulting 
hits. The reason for the exclusion of health conditions like ‘meta-
bolic syndrome’, ‘cancer’, ‘cardiovascular disease’, and ‘insulin re-
sistance’ is that this review focused on obesity only and the first 2 
steps resulted in many articles focusing on other health conditions. 
The next step (4) was ‘Obesity or Adiposity and Biomarker not 
Metabolic Syndrome not Diabetes not Cancer not Gene * not Car-
diovascular Disease not Insulin Resistance’ (955 hits), and the last 
step (5) was ‘Obes * or Adiposity and Metabol * and Biomarker not 
Gene * not Cancer not Diabetes not ‘Metabolic Syndrome’ not 
‘Cardiovascular Disease’ not Nutri * not ‘Insulin Resistance’’, re-
sulting in 644 hits. The difference with the second search step was 
the exclusion of the exact phrases of the health condition, which is 
represented by the quotation marks. Additionally, ‘Gene’ and 
some variants were also excluded because the methodological fo-
cus lies on the metabolomics approach.
 After performance of the literature review, the reference lists from 
the relevant reports and reviews were searched by hand for studies 
which were of additional interest (snowball literature search).
 Another step was the search in the journal  Metabolomics, be-
cause this journal cannot be searched via the PubMed database but 
might yield some further publications on the topic.
 Selection Criteria 
 At first, the titles and abstracts of all references were screened 
according to the inclusion criteria. Articles were included inde-
pendently of the study design. Studies were included in the analy-
sis if they: (1) were conducted in human populations (this had to 
be done a second time, because limitation of the settings on 
PubMed still resulted in some animal studies), (2) performed ei-
ther a targeted or an untargeted metabolomics analysis, (3) includ-
ed an analysis done with plasma or serum samples, and (4) focused 
on biomarkers for obesity. Studies were excluded if they were cat-
egorized as descriptive reviews or editorials.
 Articles Finally Included 
 Initially, 1,254 articles were included. Those records were 
screened and 1,142 articles were excluded due to the fact that their 
topics were not relevant or eligible for the research question of this 
review, meaning that they focused on other health conditions such 
as insulin resistance, cancer, or diabetes, were not metabolomics 
studies, or analyzed the effect of a specific nutrition on metabolism 
or health. Of the remaining 112 articles, 16 were included after 
reading of the abstracts, but 3 more were excluded because they 
were review articles, which was not apparent in the first screening 
step. Finally and after reading the full text of the articles, 13 papers 
were included (with 2 papers resulting from the snowball literature 
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nal). The individual steps of the literature review are shown in  fig-
ure 1 and a comprehensive overview of the included articles is pre-
sented in  table 1 .
 Metabolite Nomenclature 
 Fatty acids (FA), nonesterified FA (NEFA), acylcarnitines 
(CN), cholesteryl ester (CE), lysophosphatidylcholines (LPC), and 
phosphatidylcholines (PC) are mentioned as CXX:Y. In this no-
menclature, XX is the length of the carbon chain, Y is the number 
of double bonds, and OH in the formula means that the molecule 
contains a hydroxyl group. ‘a’ means that the acyl chain is bound 
via an ester bond to the backbone. ‘ ↑ ’ means higher concentrations 
in obese populations and positive associations with a marker for 
obesity, and ‘ ↓ ’ means the opposite.
 Results 
 The main results of all of the finally included articles 
were changes in the β-oxidation of FA and elevations of 
branched-chain amino acids (BCAA). Most of the studies 
(n = 8) analyzed serum samples.
 Seven studies were performed with adults as the study 
population, and 5 were done in children. The main design 
was case-control, which means the results cannot be in-
terpreted in a causal way and should rather been viewed 
as associations. An overview of the results of the different 
studies is given in  table 1 . The study characteristics can be 
found in  table 2 .
 Acylcarnitines 
 Four studies observed alterations of several CN levels. 
Oberbach et al.  [9] , for example, discovered changes in 
the levels of C2-CN ( ↓ ), C10: 1-CN ( ↑ ), C14: 1-OH-CN 
( ↑ ), C14: 2-CN ( ↑ ), C18: 1-CN ( ↑ ), and C18: 2-CN ( ↑ ) by 
analyzing the blood of the subjects after 1 h of exercise. 
Mihalik et al.  [10] observed alterations of free CN,
C14: 1-CN ( ↑ ), C16-CN ( ↑ ), C18-CN ( ↑ ), and C18: 1-CN 
( ↑ ). Wahl et al.  [11] reported significant differences in 
C12: 1-CN ( ↑ ) and C16: 1-CN ( ↑ ) between lean and obese 
subjects, and Newgard et al.  [12] analyzed the blood of 
adult subjects with median BMI values of 23.2 (lean) and 
36.6 (obese) and discovered alterations in 4 CN species, 
i.e. C3-CN ( ↑ ), C5-CN ( ↑ ), C6-CN ( ↑ ), and C8: 1-CN ( ↑ ).
 An article by Moore et al.  [13] found elevations in C3-
CN, C5-CN, and C6-CN, and another showed alterations 
in L-carnitine ( ↓ ), C3-CN ( ↑ ), and C4-CN ( ↑ )  [14] . 
 CN with 3, 4, or 5 carbon atoms are derived from 
BCAA metabolism or other amino acids (AA), while 
even-chain CN result from β-oxidation.
 A possible explanation for the alterations in middle 
and long even-chain CN levels is their central role in the 
transport of FA into the mitochondria where FA undergo 
β-oxidation. The transport form of NEFA, acyl-CoA, is 
converted to CN by carnitine-palmitoyltransferase 1 
(CPT1) to facilitate entry into the mitochondria. After 
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 Table 2.  Study characteristics
Reference Study type Age, years BMI Sample type fasted 
Netzer et al. [45] case-control lean: 38.33 ± 7.16
obese: 46.27 ± 10.48
lean: 23.88 ± 2.50 (n = 30)
obese: 34.18 ± 2.78 (n = 22)
not reported
Zeng et al. [19] case-control lean: 8.7 ± 1.74
overweight: 10.0 ± 1.15
obese: 8.9 ± 2.14
lean: 16.6 ± 1.46 (n = 16)
overweight: 22.4 ± 2.65 (n = 13)
obese: 24.6 ± 3.44 (n = 32)
plasma samples
not reported if fasted
Pietiläinen et al. [41] case-control not reported lean: 25.4 (24.5 – 26.1) (n = 7)





Oberbach et al. [9] case-control lean: 23.7 ± 1.99 (20 – 27)
obese: 24.1 ± 3.11 (20 – 30)
lean: 23 – 25 (n = 15)
obese: 30 – 45 (n = 15)
serum samples
overnight fast
(8.00 – 10.00 a.m.)
Newgard et al. [12] case-control lean: 50 (38 – 60)
obese: 52 (46 – 60)
lean: median 23.2 (n = 67)




Karlsson et al. [39] case-control lean women: 12.4 (11.7 – 14.5)
lean men: 12.6 (11.3 – 15.4)
obese women: 15.0 (11.3 – 16.4)
obese men: 11.4 (10.4 – 15.4)
lean women: 29.8 – 40.4 (n = 5)
lean men: 26.8 – 35.3 (n = 5)
obese women: 17.9 – 23.4 (n = 9)




Wahl et al. [11] case-control lean: 11.1 ± 2.8
obese: 10.9 ± 2.1
lean: 17.2 ± 2.1 (n = 40)




Mihalik et al. [21] case-control lean: 47 ± 7
obese: 43 ± 7
lean: 23.9 ± 1.8 (n = 12)
obese: 34.3 ± 3.1 (n = 14)
plasma samples
overnight fast
(10 – 12 h)
Kim et al. [14] case-control lean: 39.5 ± 1.22
obese: 39.6 ± 1.24
lean: 20.9 ± 0.14 (n = 30)
obese: 28.9 ± 0.20 (n = 30)
plasma samples
overnight fast (12 h)






obese cross-sectional: 13.3 ± 2.9
obese longitudinal cohort: 11.0 ± 1.6
obese longitudinal cohort follow-up: 
12.5 ± 1.6
obese cross-sectional: 24.9 ± 7.4 (n = 69)
obese longitudinal cohort: 26.0 ± 7.1 
(n = 17)
obese longitudinal cohort follow-up: 
27.9 ± 7.6 (n = 17)
plasma samples
overnight fast
Okada et al. [35] case-control lean: 12.6 ± 0.5
obese: 11.8 ± 3.8
lean: 17.9 ± 1.7 (n = 25 males and 28 
females)




Warensjö et al. [38] cross-sectional obese women: 40.6 ± 9.9
obese men: 40.6 ± 9.1
obese women: 23.7 ± 3.8
(n = 295)





Moore et al. [13] case-control
(PLCO study)










women: 40 – 75
men: 40 – 75
plasma samples
fasted
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CoA by CPT2, which is located in the inner membrane 
of the mitochondria. This CoA ester can then undergo 
β-oxidation.
 CN can also cross the mitochondrial membrane in 
the other direction. After CN have left the mitochon-
dria, they are excreted by either urine or bile. This de-
toxification plays a major role in cases of accumulation 
of acyl-CoA. Increasing levels of CN can be indicative of 
disorders of mitochondrial β-oxidation. This pathway 
may play a role in the development of T2DM and IR. 
One theory is that lipid oversupply results in saturation 
of the capacity of the mitochondria to oxidize FA. In this 
case, the mitochondrion becomes overloaded with FA, 
reflected by increased levels of CN in the plasma and 
decreased free carnitine levels  [15] . If β-oxidation fails 
to degrade the excess FA, this leads to aggregation of free 
FA or acyl-CoA in the plasma, which can be converted 
to other lipids such as ceramides or diacylglycerols, 
which have been related to the development of insulin 
resistance  [16] . In another hypothesis, FA oxidation is 
increased and overcomes the capacity of the TCA cycle 
to degrade acetyl-CoA. This results in a tailback of 
β-oxidation and an accumulation of short-chain CN, 
also in oxidized and hydroxyl forms. These CN may also 
contribute to insulin resistance.
 Carnitine plays another role in human metabolism. It 
is necessary not only for the oxidation of medium- and 
long-chain FA but also for the oxidation of BCAA  [17] . 
C3-CN and C5-CN are by-products of the BCAA ca-
tabolism, providing a rationale for the elevation of these 
metabolites reported in some of the studies. 
 A study in rats led to the conclusion that carnitine 
stimulates the oxidation of BCAA by increasing the con-
version of their keto analogues into carnitine esters and 
mitochondrial carnitine acyltransferase and then cata-
lyzes the formation of C3-CN and branched-chain CN 
from BCAA  [18] . 
 The accumulation of different CN and BCAA in ad-
dition to the accumulation of FA degradation products 
could thus be interpreted according to their relation dis-
cussed above.
 Branched-Chain AA 
 Four of the studies observed alterations in BCAA me-
tabolism. Zeng et al.  [19] found altered isoleucine ( ↑ ) in 
blood by examining lean, overweight, and obese chil-
dren. Kim et al.  [14] observed alterations in L-valine ( ↑ ) 
and L-leucine ( ↑ ) in their comparison of lean and obese 
adults (aged 39–40 years). Moore et al.  [13] found eleva-
tions in all 3 BCAA in obese adults. McCormack et al. 
 [20] observed elevated concentrations of leucine ( ↑ ), 
isoleucine ( ↑ ), and valine ( ↑ ) in 3 obese groups of chil-
dren.
 Wahl et al.  [11] analyzed blood of children and found 
no alterations in BCAA metabolism. They argued that 
children may exhibit early adaptive mechanisms that 
preserve a normal BCAA metabolism in the presence of 
obesity and disturbed insulin sensitivity. Mihalik et al. 
 [21] pointed out that the lower plasma BCAA in chil-
dren may be due to an increased gluconeogenetic drive 
typically seen in diabetes.
 However, more usually BCAA are elevated in obese 
subjects. Cheng et al.  [22] discovered a possible relation 
between the BCAA leucine and β-oxidation. Goichon et 
al.  [23] found that leucine supplementation altered the 
expression of several duodenal mucosal proteins, which 
are mainly involved in lipid metabolism. Therefore, the 
finding of elevated BCAA in obese persons with an as-
sumed higher fat mass seems plausible.
 Several articles indicated that elevated BCAA are sig-
nal molecules for enhanced protein synthesis  [24] and 
are related to insulin resistance via the mTOR pathway 
 [12, 25] . In a recent review, Adams  [26] showed that 
obesity, insulin resistance, and T2DM are conditions 
with elevated blood concentrations of one or more 
BCAA, branched-chain keto acids, and/or short-chain 
carnitine esters derived from partial BCAA catabolism 
in human adults. Since insulin resistance is more preva-
lent in overweight and obese individuals compared to 
lean persons, it is important to consider that the high 
circulating BCAA and derivatives in the aforementioned 
studies were also tracking insulin resistance and not just 
adiposity per se  [26] . 
 Moore et al.  [13] showed that 3-methyl-2-oxobuty-
rate ( ↑ ), α-hydroxyisovalerate ( ↑ ), 4-methyl-2-oxopen-
tanoate ( ↑ ), and 3-hydroxyisobutyrate ( ↑ ) are associated 
with the BMI. These short-chain acyls are degradation 
products of BCAA and are converted to short-chain CN. 
Neither BCAA nor short-chain CN are likely to be re-
sponsible for the adverse effects, but the keto acids which 
are generated during BCAA degradation may have path-
ological consequences. Further studies should increase 
the focus on these keto acids.
 Amino Acids 
 Six articles identified AA other than BCAA as indica-
tive of obesity; these are: the aromatic AA phenylalanine 
( ↑ )  [12, 13] ( ↓ )  [19] , tyrosine ( ↑ )  [12–14 ], and tryptophan 
( ↑ )  [12, 14] ; the sulfur-containing AA methionine ( ↓ ) 
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cine ( ↑ )  [9] ( ↓ )  [13] and alanine ( ↑ )  [12] ; the acidic AA 
(and their amides) glutamine ( ↑ )  [9] ( ↓ )  [11] , glutamate 
( ↑ )  [13] , glutamate/glutamine ( ↑ )  [12] , aspartate/aspara-
gine ( ↑ )  [12] , and asparagine ( ↓ )  [13] ; the basic AA argi-
nine ( ↑ )  [12] and histidine ( ↓ )  [13] ; the hydroxyl AA ser-
ine ( ↓ )  [19] , and the nonproteinogenic AA kynurenine 
( ↑ ). Furthermore, there were differences in the acetyla-
tion product N-acetylglycine ( ↓ ) and the AA degradation 
products 3-(4-hydroxyphenyl) lactate ( ↑ ) and 2-hy-
droxybutyrate (AHB) ( ↑ )  [13] .
 In a metabolomics analysis of serum from 38- to 
52-year-old participants, Xu et al.  [27] found that several 
AA including alanine, proline, phenylalanine, and gluta-
mine were raised in insulin-resistant subjects. This pro-
vides another ‘hint’ that some biomarkers for the obese 
state are possible early markers for insulin resistance.
 Several articles found associations between aromatic 
acids like phenylalanine  [28] and insulin secretion or 
T2DM. Würtz et al.  [29] , for example, concluded that el-
evated branched-chain and aromatic AA levels precede 
the development of insulin resistance already in early 
adulthood.
 Adams  [26] reviewed that increased circulating con-
centrations of phenylalanine and tyrosine have been re-
ported in the obese, insulin-resistant, or T2DM state in 
humans. He concluded that changes in these metabolites 
often go hand in hand. 
 Lipids 
 Lipids, another class of metabolites associated with 
obesity in some publications, can be determined as a mo-
lecular species or through the FA composition of single 
lipid classes such as glycerophopholipids  [30, 31] , NEFA 
 [32] , and acylglycerols  [33] , as well as that of all lipid 
classes (total FA; tFA)  [34] . Thus, comparison of the re-
sults of different reports is challenging.
 Okada et al.  [35] found alterations in the composition 
of the tFA C14: 0 ( ↑ ), C16: 0 ( ↑ ), C16: 1n-7 ( ↑ ), C18: 1n-9 
( ↑ ), C20: 1n-9 ( ↑ ), C20: 3n-6 ( ↑ ), C18: 3n-3 ( ↑ ), and
C18: 2n-6 ( ↓ ), as well as C20: 2n-6 ( ↓ ), while Newgard et 
al.  [12] showed increases in the absolute concentration 
of most analyzed tFA. Thus, two different assumptions 
can be made. First, the absolute FA concentration in the 
blood is increased in obese subjects (this is in accordance 
with elevated triacylglycerol levels)  [33] , and second, and 
maybe more importantly, the composition of FA in the 
blood changes. Elevated percentages of monounsaturat-
ed FA (MUFA) reflect an increase in stearoyl-CoA de-
saturase (SCD) activity  [35] , and this means a higher rate 
of conversion from saturated FA to MUFA. SCD is a Δ9 
desaturase. Increased SCD activity and higher levels of 
MUFA were found in many publications  [36, 37] . An-
other alteration of FA metabolism is represented by al-
terations of polyunsaturated FA (PUFA) percentages. 
Warensjö et al.  [38] analyzed the FA composition of se-
rum CE and showed a positive correlation of Δ6 desatu-
rase as well as a negative correlation of Δ5 desaturase 
activity with markers for obesity in adults by calculating 
the ratios of the corresponding FA  [40] . They also showed 
an increase in Δ9 desaturase activity, which is in agree-
ment with the results of Okada et al.  [35] . A decrease in 
Δ5 desaturase in obese subjects would result in a stronger 
increase in C20: 3n6 compared to C20: 4n6. This is also in 
agreement with Okada et al.  [35] , who found significant-
ly higher levels of C20: 3n6 percentages in obese subjects 
and no significant difference for C20: 4n6 between obese 
and control subjects.
 An additional paper, which analyzed the FA composi-
tion of phospholipids (PL), found the concentrations of 
C22: 6n-3 ( ↓ ), C24: 1n-9 ( ↑ ), the C24: 1n-9-to-C24: 0 ratio 
( ↑ ), C20: 0 ( ↑ ), and C22: 0 ( ↑ ) to be altered in females and 
that of C20: 0 ( ↑ ) and the C24: 1n-9-to-C24: 0 ratio ( ↑ ) to 
be altered in males  [41] , which also reflects increased 
SCD activity. Interestingly, they found only small chang-
es in PUFA percentages ( table 1 ). PL composition was 
also determined by Kim et al.  [14] , who confirmed the 
decreased Δ5 desaturase activity which was especially in-
fluenced by higher levels of 20: 3n6. Thus, one should fo-
cus on C20: 3n6 (dihomo-γ-linolenic acid) in further 
studies and not only on C20: 4 and C22: 6. Kim et al.  [14] 
showed minor effects on MUFA, Δ9 desaturase activity, 
and other PUFA.
 Another lipid class which is discussed in obesity re-
search is plasma NEFA, reflecting the FA composition 
and activity of adipose tissue for certain FA species  [32] . 
Newgard et al.  [12] reported increased levels of NEFA 
C14: 0 ( ↑ ), C16: 0 ( ↑ ), C16: 1 ( ↑ ), C18: 1 ( ↑ ), and C20: 4n6 
( ↑ ) but no change in C18: 0, C18: 2n-6, or C18: 3n-3 in 
obese participants  [12] , while Zeng et al.  [19] showed no 
difference for any determined NEFA. The fact that obe-
sity and an increased fat mass do not necessarily result in 
a greater release of NEFA from adipose tissue or higher 
NEFA levels was systematically reviewed by Karpe et al. 
 [40] . The authors reviewed studies which were related to
‘metabolomics’. Thus, articles that just dealt with FA 
composition in relation to obesity were not included 
during the review process.
 Aside from FA composition, the determination of 
molecular species is becoming more important, especial-
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turbed values for LPC and PC species. Oberbach et al.  [9] 
described PCaa 42: 0 ( ↑ ), PCaa 32: 0 ( ↓ ), PCaa 32: 1 ( ↓ ), 
and PCaa 40: 5 ( ↓ ) as possible biomarkers for obesity. 
Wahl et al.  [11] showed significant differences for PCaa 
C34: 1 ( ↓ ), PCaa C34: 2 ( ↓ ), PCaa C34: 3 ( ↓ ), PCaa C36: 2 
( ↓ ), PCaa C36: 3 ( ↓ ), PCaa C38: 2 ( ↓ ), LPCa C18: 1 ( ↓ ), 
LPCa C18: 2 ( ↓ ), and LPCa C20: 4 ( ↓ ). Kim et al.  [14] 
found LPC C14: 0 ( ↑ ), LPC C16: 0 ( ↑ ), LPC C18: 0 ( ↑ ), and 
LPC C18: 1 ( ↓ ) to be different between lean and obese 
subjects. Pietiläinen et al.  [41] found PC 38: 3 ( ↓ ), PC 
O-16: 0/20: 3 ( ↓ ), PC 38: 2 ( ↓ ), GPEtn O-36: 3 ( ↓ ), GPEtn 
38: 1 ( ↓ ), PC 34: 3 ( ↓ ), PC O-38: 7 ( ↓ ), GPEtn 42: 6 ( ↓ ), PC 
40: 6 ( ↓ ), PC O-34: 1 ( ↓ ), PC 36: 4 ( ↑ ), PC 38: 6 ( ↑ ), PC
18: 1/0: 0 ( ↑ ), PC 16: 0/0: 0 ( ↑ ), PC O-20: 3/0: 0 ( ↑ ), PC 38: 4 
( ↑ ), PC 0: 0/16: 0 ( ↑ ), PC 34: 4 ( ↑ ), PC 20: 4/0: 0 ( ↑ ), PC
18: 2/0: 0 ( ↑ ), PC 0: 0/20: 4 ( ↑ ), PC 18: 0/0: 0 ( ↑ ), and PC 16: 
 0/20: 4 ( ↑ ). 
 The results seem to be inconsistent and their interpre-
tation very complex in the context of this review and 
therefore a global summary cannot be given. Further-
more, the data are complex in relation to the FA content 
since, for example, PC 36: 3 is the sum parameter for
PC 16: 0/20: 3, PC 14: 0/22: 3, PC 16: 1/20: 2, PC 18: 0/18: 3, 
and PC 18: 1/18: 2. 
 Limitations 
 One limitation of the described studies is that the dif-
ferent studies of metabolomics were undertaken in sub-
jects of differing ages, and there might be age-related dif-
ferences in metabolism. Besides that, growth might have 
an impact on metabolism, especially in relation to the 
metabolic pathway of BCAA. Mihalik et al.  [21] and 
Wahl et al.  [11] argue that there is some evidence for 
early adaptive mechanisms in children, who can preserve 
a normal BCAA metabolism even in the obese state. Bio-
marker studies should be interpreted with respect to this 
suggestion. 
 Another restriction could be the definition of obesity. 
For a long time, the BMI was the standard measurement 
criterion, with a cutoff point of 30, but recently a few 
limitations of this measurement have become apparent, 
e.g. the fact that the Asian population does not fit the cri-
teria for the BMI borderlines  [43] . Currently, more and 
more research is being conducted using measures of 
body composition including the waist-to-hip ratio, the 
DEXA, and skinfold measurements as indicators of the 
obese state in humans. 
 In most cases, sex differences should be interpreted 
more clearly because some studies suggested that there 
are differences between men and women according to 
the surrogate measurements BMI and waist circumfer-
ence. Camhi et al.  [44] , for example, found that there 
were significant differences for all fat depots for a given 
level of BMI or waist circumference between sexes. In 
some studies, the gender of the participants was not re-
ported or the study was confined to male subjects ( ta-
ble  2 ). Many of the studies were conducted using a 
Biocrates kit and therefore resulted in similar metabolic 
findings and conclusions. Most of the studies had small 
sample sizes, so the effects measured may have been due 
to randomness. All studies were case-control or cross-
sectional studies, so no causality but rather only associa-
tions could be concluded.
 The strength of this review is the fact that it provides 
a very comprehensive overview of the current state of the 
knowledge and research on biomarkers for obesity in 
adults as well as in children. The metabolites suggested 
as biomarkers in the presented studies represent very 
similar metabolic pathways that could be disturbed in the 
obese state, since most of the literature on this topic has 
discovered alterations in the BCAA concentrations and 
in FA oxidation.
 Conclusion 
 Obesity has become a global public health burden. 
Since consumption of the ‘Western diet’ is spreading 
across the world, the burden is likely to increase over the 
next years, especially if no preventive strategies are dis-
covered, based on a foundation of knowledge of the un-
derlying mechanisms.
 Metabolomics is a tool with the potential for major 
influence on public health preventive strategies since it 
provides background knowledge of the underlying 
mechanisms of obesity and associated diseases such as 
insulin resistance and T2DM. 
 The metabolites that have repeatedly been identified 
in several studies are BCAA, i.e. isoleucine, leucine, and 
valine, the AA glutamine, methionine, and phenylala-
nine, the LPC C18: 1, and several CN. The use of BCAA 
as biomarkers for obesity should be handled with care 
since BCAA are also indicative of and possible biomark-
ers for insulin resistance and T2DM  [42] . Elevated levels 
of BCAA may be early signs of later development of one 
of these diseases. Future studies should focus on altera-
tions in BCAA metabolism. More research on the bio-
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